BACKGROUND: Phosphodiesterase type-1 (PDE1) hydrolyzes cAMP and cGMP and is constitutively expressed in the heart, although cardiac effects from its acute inhibition in vivo are largely unknown. Existing data are limited to rodents expressing mostly the cGMP-favoring PDE1A isoform. Human heart predominantly expresses PDE1C with balanced selectivity for cAMP and cGMP. Here, we determined the acute effects of PDE1 inhibition in PDE1C-expressing mammals, dogs, and rabbits, in normal and failing hearts, and explored its regulatory pathways.
H
eart failure (HF) affects an estimated 30 to 50 million patients worldwide. Despite recent therapeutic advances, its prevalence is increasing, in part, because of a fall in mortality, but also because of higher rates of major comorbidities such as obesity, diabetes mellitus, and age. 1 A major factor underlying cardiac dysfunction in HF resides in second messenger signaling defects coupled to cAMP and cGMP. cAMP stimulates protein kinase A and exchange protein activated by cAMP, acutely enhancing excitation-contraction coupling and sarcomere function. 2 Cyclic GMP acts as a brake on this signaling by activating protein kinase G. 3, 4 . Both cyclic nucleotides have relevant vascular and fibroblast activity, reducing vessel tone, altering permeability and proliferation, and suppressing fibrosis. [5] [6] [7] They are synthesized by adenylyl or guanylyl cyclases and degraded (hydrolyzed) by phosphodiesterases (PDEs) 8, 9 to provide tissue-and cell-specific intracellular nanoregulation. 10 From a therapeutic standpoint, PDEs are of particular interest because their structure is amenable to selective small-molecule inhibition, and their cell-specific expression provides better organ targeting. 11 There are 11 main PDE members expressed as >100 isoforms, with PDE4, PDE7, and PDE8 being highly selective for cAMP, and PDE5, PDE6, and PDE9 being highly selective for cGMP. The remaining PDEs hydrolyze both with selectivity depending on biological conditions and isoforms. 11, 12 The heart and myocytes express mRNA for all but PDE6, and functional roles have been identified for PDE1 through 5, PDE8, and PDE9. Inhibitors of several of these PDEs have been translated to humans. PDE3 inhibitors are used as inotrope/vasodilators for acute HF, 13 and PDE5 inhibitors for pulmonary hypertension and erectile dysfunction, 14 although cardiac indications have also been explored. [15] [16] [17] PDE4 inhibitors are used for forms of chronic pulmonary disease, 18 whereas PDE9 inhibitors have been tested for Alzheimer disease, 19 and recent data suggest they may hold promise for HF as well. 20 PDE1 is constitutively and robustly expressed in the heart. It is activated by a Ca 2+ /calmodulin-binding domain and provides a substantial percentage of in vitro cAMP and cGMP hydrolytic activity in mammals, including humans. 21, 22 It is remarkable, however, that virtually nothing is known about its role in acute cardiovascular regulation. PDE1 is expressed as 3 isoforms: PDE1A and PDE1C are in the heart and vessels, whereas PDE1B is primarily found in the brain. The isoforms are not redundant, because PDE1A is >30 times more selective for cGMP, whereas PDE1C has similar affinities for both cyclic nucleotides. 9 Humans predominantly express PDE1C in the heart, whereas rodents express mostly PDE1A. Yet all reported cardiovascular studies are from rodents. In mice, nonisoform selective PDE1 inhibition attenuates cardiac hypertrophy and fibrosis induced by 1 to 2 weeks of isoproterenol or angiotensin infusion, 23, 24 and is coupled to enhanced cGMP levels. Mice genetically lacking PDE1C are also protected against pressure overload, 25 although here the mechanism relates to cAMP. PDE1 also regulates sinoatrial beat frequency via cAMPstimulated HCN4 potassium channels. 26 The cardiovascular effects of PDE1 inhibition in mammals similar to humans (mostly expressing PDE1C) have not been reported. In addition, whether such effects are altered in HF or by β-adrenergic stimulation/blockade is unknown. These are all essential preclinical questions if small-molecule PDE1 inhibitors are to find applications in human heart disease.
The recent development of ITI-214, 27 a potent and highly selective PDE1 inhibitor first studied for treat-
Clinical Perspective
What Is New?
• Selective inhibition of phosphodiesterase (PDE) type 1, a dual (cAMP and cGMP) PDE, with ITI-214 induces positive inotropic, lusitropic, chronotropic, and arterial vasodilatory effects in mammals expressing the dominant human isoform, PDE1C.
• The effects occur via cAMP modulation and are observed in failing hearts.
• ITI-214 contractile increase is insensitive to β-adrenergic blockade or heart rate increase, but inhibited in vivo by adenosine receptor (A 2B ) blockade.
• Isolated myocytes reveal differences between PDE1 and PDE3 inhibition.
• PDE3 inhibition augments β-receptor agonism, and when combined with adenyl cyclase activation, augments cell shortening and calcium transients, whereas PDE1 inhibition enhances function without calcium increase.
What Are the Clinical Implications?
• ITI-214 has been previously completed in 4 phase I studies, and is currently under study for Parkinson's disease (NCT03257046).
• A phase Ib/IIa safety and tolerability study with noninvasive hemodynamic data in patients with heart failure is also underway (NCT03387215).
• Adenosine signaling is cardioprotective against ischemic and heart failure stress, so the finding that PDE1 couples to A 2B receptor signaling rather than β-adrenergic signaling suggests the potential for providing cardioprotection.
• In contrast to PDE3 inhibition, myocyte results show negligible change in calcium transients with PDE1 inhibition despite improved cell shortening, suggesting different cAMP regulation and potentially a safer clinical profile than PDE3. 
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ing neurodegenerative and neuropsychiatric disease, 28 offers a new tool to address these questions. To our knowledge, it is the only PDE1 inhibitor yet studied in humans (NCT01900522 and NCT03257046), so far, for neurocognitive diseases, with a phase Ib/IIa safety/ tolerability dosing study underway in humans with HF (NCT03387215). It is also the only compound for which sufficient quantities are available for large-animal testing. The current study determined cardiovascular effects of ITI-214 in the dog and rabbit, both of which primarily express PDE1C, and further assessed its impact on failing hearts. We dissected signaling pathways engaged by PDE1 inhibition in the intact rabbit and isolated rabbit myocytes, where comparisons were also made with that of PDE3 inhibition. The data reveal acute positive inotropic, lusitropic, and arterial vasodilator effects in vivo that persist in HF, are not impacted by concomitant β-adrenergic stimulation or blockade, but regulate adenyl cyclase-coupled activity and require adenosine receptor A 2B -receptor (A 2B R) signaling in vivo. They differ from PDE3 with respect to calcium handling and interaction with β-adrenergic stimulation.
METHODS
The authors declare that all supporting data are available within the article and in its online-only Data Supplement. -fold selectivity toward all other PDE enzyme families. 28 Additional pharmaceuticals were dobutamine (Hospira Inc), esmolol HCl (Mylan), cilostamide, MRS1754 (Tocris Bioscience), Hespan (6% Hetastarch in 0.9% NaCl, B. Braun Medical Inc), forskolin, isoproterenol HCl, and 3-isobutyl-1-methylxanthine (Sigma-Aldrich).
Pharmaceuticals

Animal Studies
All animal study procedures were performed in accordance with the Guide to the Care and Use of Laboratory Animals, and approved by the Johns Hopkins University Institutional Animal Care and Use Committee.
In Vivo Canine Studies
Adult mongrel dogs (25-30 kg; n=6) were chronically instrumented with left ventricular sonomicrometers, micromanometers, inferior vena caval cuff occluders, and indwelling arterial and venous catheters for conscious pressure-volume (PV) hemodynamic analysis. Dogs were studied in the conscious state before and after inducing dilated cardiomyopathy by tachypacing. Details of this preparation have been reported. 29 On separate days, dogs were administered oral (0.1-10 mg/kg) or intravenous (0.01 and 0.1 mg/kg) ITI-214 with and without concomitant β-adrenergic receptor stimulation by dobutamine (10 μg·kg -1 ·min -1 ). Intravenous infusion data were measured over 15 minutes post bolus injection or after steady-state infusion was achieved. Oral ITI-214 was provided in gelatin capsules encased in peanut butter, and hemodynamic data were recorded over the ensuing 2 hours. Based on plasma levels and responses in normal and HF dogs, an optimal dose (10 mg/kg) was identified and is reported. This dose was repeated on a separate day, with dogs first receiving dobutamine, then, after rebaseline, oral ITI-214, and after 2 hours, repeat dobutamine testing. Intravenous ITI-214 was dissolved in 0.05 mol/L citrate-phosphate buffer (pH 3.2), and administered via a central venous catheter.
In Vivo Rabbit Studies
New Zealand White rabbits (male, 2-3 kg, n=25) were sedated with 35 mg/kg ketamine and 5 mg/kg xylazine, intubated and ventilated (model 683, Harvard Apparatus), and anesthesia was maintained by isoflurane inhalation (1%-2%). A PV catheter (SPR-894, Millar, Inc) was inserted via the common carotid artery and advanced to the left ventricle apex, and a 2F pacing catheter (Arrow Intern, Inc) was positioned in the right atrium via the right jugular vein to provide atrial pacing. A 4F Berman balloon catheter (AI-07134, Teleflex) was positioned in the inferior vena cava via a femoral vein and used to transiently reduce venous return to assess PV relations. Volumes were calibrated by the hypertonic saline method, 30 with an assumed gain of 1.0. Rabbits were infused with 6% hetastarch in saline during the procedure to stabilize arterial pressure. All pharmaceuticals were administered intravenously in 2 protocols: ITI-214 (bolus 0.1 mg/kg administered over 1 minute) with or without 15-minute pretreatment with (1) 
In Vivo Mouse Studies
Adult C57BL/6J mice (3 months, n=5-7) were anesthetized, instrumented with a miniature PV catheter, and studied as described. 30 ITI-214 was delivered at 0.1 and 0.5 mg/kg IV over a 30-second period, and cardiovascular function was recorded for 10 minutes.
Myocardial Tissue Analysis
Heart tissue was rapidly excised from euthanized adult C57BL/6J mice, Sprague Dawley rats, mongrel dogs, and New Zealand White Rabbits, washed, and then frozen in liquid nitrogen. Human myocardial tissue was obtained from donor control hearts (n=14) and end-stage cardiomyopathic hearts (n=14) from a tissue bank at the University of Pennsylvania. Both types of heart tissue were harvested under controlled surgical procedures using ice-cold cardioplegia, transported on ice, and snap-frozen in liquid nitrogen shortly thereafter.
Isolated Myocyte Studies
New Zealand White Rabbits (male, 2-3 kg, n=13) were sedated as above, and the heart perfused retrograde using a Langendorff preparation to isolate left ventricular myocytes. Details of the procedure are provided in the Methods in the online-only Data Supplement.
Real-Time Quantitative Polymerase Chain Reaction Analysis
RNA was extracted and analyzed using standard protocols (see the Methods in the online-only Data Supplement).
Protein Immunoblot Analysis
Details of protein immunoblot analysis are provided in the Methods in the online-only Data Supplement.
Liquid Chromatography-Tandem Mass Spectrometric Analysis of ITI-214 in Plasma
Blood was collected in dipotassium ethylenediaminetetraacetic acid tubes, centrifuged at 2000g for 15 minutes, and the plasma fraction frozen. ITI-214 levels were assessed by a rapid, sensitive liquid chromatography-tandem mass spectrometric method (details in the Methods in the online-only Data Supplement). In an initial dose titration study, normal conscious dogs were exposed to oral and intravenous doses of ITI-214 ranging from 0.1 to 10 mg/kg, and pharmacodynamic assays were performed. With 10 mg/kg by mouth, plasma ITI-214 free base concentrations were 103.9±8.5 ng/mL at 120 minutes post dose in normal dogs, and 178.4±100.5 ng/mL in HF dogs. At 0.1 mg/kg IV, in normal dogs, plasma ITI-214 concentrations peaked within minutes, falling to 211.2±60.7 at 10 minutes, and 94.5±21.2 ng/mL at 30 minutes. These levels were somewhat higher in failing dogs (441.4±92.5 and 184.9±28.9 ng/mL at 10 and 30 minutes, respectively ( Figure  I in the online-only Data Supplement). Rabbit dosing at 0.1 mg/kg yielded 213±88 ng/mL at 15 minutes. Mouse plasma levels 15 minutes after intravenous dosing were 334.1±74 ng/mL. Plasma levels of 100 to 200 ng/mL correspond to free plasma concentrations of 1 to 2 nmol/L ITI-214 (which is >99% plasma protein-bound), above the K i for recombinant PDE1, but far below the K i of other PDEs.
28
Cyclic Nucleotide Assay
Details for cAMP and cGMP plasma analysis are provided in the Methods in the online-only Data Supplement.
Data Analysis and Statistics
Hemodynamic recordings were obtained with a custom AD acquisition system or Powerlab (AD Systems) and analyzed with custom software (WinPVAN, JHU Baltimore) as described. 30 Results are presented as means±SEM. For steady state analysis, multiple cycles (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) were time averaged to generate a single beat that was analyzed. For multiple-beat PV analysis, data during inferior vena cava occlusion were used to derive load-independent measures of contractility (end-systolic elastance [Ees], preload-recruitable stroke work, maximal rate of pressure rise normalized to instantaneous pressure [dP/ dt max /IP], rate constant of relaxation, and various other hemodynamic indexes as previously described). 29 Myocyte shortening and calcium data were analyzed using IonOptix software (MyoCam). Data were statistically analyzed using GraphPad Prism 7 (GraphPad Software, Inc). Western blot and quantitative polymerase chain reaction data were analyzed using 2-way ANOVA to assess the interaction of isoform and disease. In vivo time-series data were examined using 2-way repeated-measures ANOVA with the post hoc Sidak multiple comparisons test to assess the interaction of time and drug intervention. One-way ANOVA (or Kruskal-Wallis test, if the D'Agostino and Pearson normality test failed) with post hoc multiple comparisons testing, and unpaired t test (or MannWhitney test) were also used where appropriate and are indicated in the figure legends.
RESULTS
PDE1A Versus PDE1C Isoform Expression in Dog and Rabbit Versus Human
To establish an experimental model in a mammal expressing primarily PDE1C in the myocardium, protein and gene expression were examined in humans, dogs, rabbits, rats, and mice. Dogs and rabbits express primarily PDE1C ( Figure 1A and 1B), with a smaller amount of PDE1A and opposite the profile in rats or mice ( Figure  II in the online-only Data Supplement). The expression profile is not significantly altered by HF in dogs. Human left ventricle overwhelmingly expresses PDE1C at the transcript level, although some PDE1A is present. At the protein level, both are present, with PDE1C dominating in normals, and PDE1A increasing with end-stage HF ( Figure 1C ). PDE1B is undetected in the heart but present in the brain for all the species.
Acute PDE1 Inhibition Alters Cardiovascular Function in Normal and Failing Canine Hearts
To assess the cardiac effects of acute PDE1 inhibition, we obtained PV relationships in intact dogs with healthy or failing hearts and analyzed hemodynamic and cardiac mechanics at baseline and 120 minutes after a single oral ITI-214 dose (10 mg/kg). This time point was based on the pharmacokinetic data described in Methods. Figure 2A shows representative PV loops and relationships for a control and HF dog at the 2 time points. There was an increase in contractility (higher end-systolic elastance) with little change in left ventricle preload (end-diastolic volume) or systolic pressure. Summary data for both conditions are provided in Figure 2B and Table I in the online-only Data Supplement. In normal dogs, ITI-214 increased heart rate (HR), reduced systemic vascular resistance, and increased cardiac output, without altering systolic blood pressure.
Load-insensitive indexes of contractility (dP/dt max /IP and preload-recruitable stroke work) increased. Relaxation reflected by peak rate of pressure decline (dP/dt min ) and relaxation time constant (tau) also improved. With HF, basal contractility was depressed and ITI-214 increased inotropy and induced vasodilation, similar to controls. The rise in HR was blunted in HF animals (P=0.07 for interaction by 2-way ANOVA). Thus, ITI-214 produced a net rise in cardiac output (+50% in controls, +32% in HF) without altering systemic pressure.
Intravenous ITI-214 produced similar effects in both normal and HF conditions, but the response was more rapid, peaking after 5 to 10 minutes ( Figure III in the online-only Data Supplement). At 0.01 mg/kg (23.6±8.6 ng/mL plasma ITI-214 concentrations at 10 minutes), responses in all but HR were negligible. However, at 0.1 mg/kg (211.2±60.7 ng/mL plasma ITI-214 concentrations at 10 minutes), positive chronotropic, inotropic, lusitropic, and vasodilator responses were observed, with a net rise in cardiac output similar to that with 10 mg/kg oral dose. These effects were again slightly abated with HF, but positive inotropy, lusitropy, and vasodilation remained significant.
Hemodynamic Effects of PDE1 Inhibition in Dogs Are Additive to β-Adrenergic Stimulation
The acute cardiovascular responses to ITI-214 in the conscious dog suggested it primarily influences cAMP signaling over cGMP. This raised the question of whether its net impact was redundant to or amplified by coactivation of the β-adrenergic receptor (β-AR) pathway. This was tested by administering 10 μg·kg -1 ·min -1 dobutamine with or without concurrent 10 mg/kg ITI-214. Dobutamine increased PV loop area (stroke work) and shifted the upper corner of each loop to the left (increased contractility), and adding ITI-214 enhanced both of these effects (Figure 3A) . These effects were additive, not synergistic. This was determined from the drug interaction term by 2-way 
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ANOVA ( Figure 3B . P values indicate interaction, none of which were significant [ie, lines were generally parallel]).
In normal dogs, plasma cAMP increased with dobutamine infusion but not with ITI-214. When combined, the same increase in cAMP was observed as with dobutamine alone (Figure 4) . ITI-214 alone also did not elevate plasma cAMP in HF dogs, whereas dobutamine+ITI-214 did. Plasma cGMP was unchanged at all conditions in normal and HF dogs. Both baseline cAMP and cGMP were significantly greater in HF versus control dogs. .01 versus baseline, paired t test. CO indicates cardiac output; dP/dt max /IP, peak rate of pressure rise normalized to instantaneous pressure; dP/ dt min , peak rate of pressure decline; HF, heart failure; HR, heart rate; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; PRSW, preload-recruitable stroke work; PV, pressure-volume; SBP, systolic blood pressure; SVR, systemic vascular resistance; and tau, relaxation time constant.
Cardiovascular Effects of PDE1 Inhibition in Rabbits Are Similar to Dogs, and Unaltered by β-AR Blockade but Suppressed by Adenosine A 2B R Inhibition
cAMP is principally generated by transmembrane adenylyl cyclase activated via stimulatory G protein (G s ), with β-adrenergic (β-AR), adenosine (notably A 2B ), glucagon, prostanoids, histamine, and serotonin receptors all coupling to G s in cardiomyocytes. 2 Here, we focused on β-AR and adenosine receptors, examining the A 2B R, in particular, because it is reported to directly stimulate cAMP-dependent contractility. 2, 31 Anesthetized rabbits received intravenous ITI-214 at 0.1 mg/kg (dose based ·min -1 dobutamine, and dobutamine+10 mg/kg ITI-214. The effects of ITI-214 or dobutamine alone were generally matched, and their combination was additive (eg, no interaction effect between drugs; lines as shown were effectively parallel). P values for each graph are for this interaction term from 2-way repeated-measures ANOVA. *P<0.05, †P<0.01 versus baseline (ie, dobutamine=0), ‡P<0.05, §P<0.01 versus control (n=4-5). CO indicates cardiac output; DOB, dobutamine; dP/dt max /IP, peak rate of pressure rise normalized to instantaneous pressure; HR, heart rate; LV, left ventricle; PRSW, preload-recruitable stroke work; and SVR, systemic vascular resistance. Table II in the online-only Data Supplement. As in the dog, acute PDE1 inhibition alone increased cardiac output because of a rise in contractility (Ees and preload-recruitable stroke work rose by 50%), modestly elevated HR, and lowered systemic resistance, and did not alter systolic pressure. The relaxation rate was faster (Table II in To test the role of different cAMP-stimulation pathways on ITI-214 effects, we repeated these experiments with pretreatment with esmolol to block β-AR receptors or MRS-1754 to block A 2B Rs ( Figure 5A and 5B, Table II in the online-only Data Supplement). Each blocker was first infused and data obtained after 10 to 15 minutes before the addition of ITI-214. Neither blocker altered resting cardiac function or hemodynamics alone (Table  II in HR itself influences cardiac function and hemodynamics, and, because this differed between experimental animal groups, we controlled for HR using atrial pacing set at ≈20% above the sinus rate. ITI-214 induced nearly identical responses under these conditions as when HR was allowed to increase; these effects were again unaltered by esmolol but suppressed by MRS-1754 ( Figure 5C , Figure VI in the online-only Data Supplement).
Circulation
ITI-214 Has Mild Vasodilator but no Inotropic Effects in Intact Mice
The isoform disparity among dogs, rabbits, and mice predicted that the mouse might respond differently to acute ITI-214, because PDE1A favors cGMP over cAMP hydrolysis. To test this, we measured PV relations performed studies in anesthetized mice, administering the same concentration (0.1 mg/kg IV) as in dogs and rabbits (Table III in the online-only Data Supplement). At this dose, there was only a small rise in cardiac output consistent 
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with transient arterial vasodilation; no other parameters displayed significant differences. At a much higher dose (0.5 mg/kg), we observed chronotropy (+4%) and reduced arterial resistance (-15%) associated with a rise in cardiac output, but no increases in contractility. Thus, the mouse hemodynamic response had similarities with dogs and rabbits with respect to systemic vasodilation and heart rate increase, but not inotropy.
Effects of ITI-214 on Myocyte Contractility and Calcium in Comparison With PDE3 Inhibition in Isolated Rabbit Myocytes
We next turned to isolated rabbit myocytes to determine the effect of PDE1 inhibition on cardiomyocyte contraction and whole-cell Ca 2+ transients, and compared the results with those with a PDE3 inhibitor, cilostamide (Cil, 1 µmol/L). Figure 6A shows example time tracings. Percentage of sarcomere shortening (%SS) and peak-Ca 2+ transients rose and their decay kinetics accelerated in cells treated with Cil; however, this was not observed with ITI-214 (1 µmol/L).
To compare the influence of PDE1 and PDE3 in modulating β-AR signaling, cells were first exposed to a nonsaturating dose of isoproterenol (Iso, 40 nmol/L near half maximal effective concentration (EC 50 ) based on dose-response curve Figure VII in the online-only Data Supplement), then Iso combined with either Cil or ITI-214. As expected, Iso increased %SS and peak-Ca 2+ , and quickened relaxation times. Addition of Cil further increased %SS (P=0.0002), and peak-Ca 2+ remained elevated over baseline (P=0.001). By contrast, when ITI-214 was added to Iso, %SS did not change further, and peak-Ca 2+ was no longer significantly different from preIso baseline ( Figure 6C and 6D) . We conclude that PDE1 does not interact with β-AR signaling, but PDE3 does.
An alternative approach to augmenting cAMP independent of β-AR is to directly stimulate adenyl cyclase using forskolin (Fsk). We again performed a dose-response study, identifying a nonsaturating Fsk dose that still generated significant inotropic effects (1 µmol/L, Figure VIII in the online-only Data Supplement). When Cil was added to Fsk, we observed an increase in %SS, peak-Ca 2+ transient, and faster decay of the Ca 2+ transient. When ITI-214 was added to Fsk, %SS rose as with Cil, but there was no corresponding increase in peak Ca 2+ transient, which was significantly less than that with Cil. It is interesting to note that Fsk+ITI-214 enhanced the Ca 2+ decay rate in a way similar to Cil ( Figure 6E and 6F) .
Last, we compared the effect of Iso, Cil, ITI-214, and their combination on myocyte cAMP. Despite increases in %SS and Ca 2+ transients, Iso, Cil, or their combination did not measurably increase whole-cell cAMP. Neither did ITI-214 and ISO+ITI-214. This is consistent with prior studies showing that locally generated cAMP from β-AR and its modulation by PDE3 occur in local subcellular domains that are not easily detected in whole-cell lysates. 32 Fsk resulted in a rise in cAMP that was further increased by the addition of ITI-214 but not Cil. The latter reached about half the maximal change as assessed by adding the broad PDE inhibitor 3-isobutyl-1-methylxanthine to Fsk. Taken together, these data identify a different pool of cAMP under PDE1 regulation that is not modulated by β-AR but can be revealed with direct adenyl cyclase stimulation.
DISCUSSION
This study reveals potent acute cardiovascular effects from a highly selective pan-isoform PDE1 inhibitor (ITI-214) tested in mammalian hearts that, like humans', principally express PDE1C. The positive inotropy, chronotropy, and vasodilation effects are most consistent with modulation of cAMP, and were not seen in mice, where the dominant isoform is PDE1A, which favors cGMP hydrolysis. The combination of effects in both dogs and rabbits results in a rise in cardiac output with negligible changes in cardiac preload and arterial systolic pressure. Unlike in vivo β-AR stimulation, PDE1 inhibition does not elevate plasma cAMP, nor are its cardiovascular effects blunted by β-AR blockade or constant rate pacing. By contrast, these effects were markedly suppressed in the intact rabbit by concurrent A 2B R inhibition, supporting the engagement of an alternative cAMP pathway. Last, in studies performed in rabbit myocytes, we reveal disparities between PDE1 and PDE3 inhibitory effects. PDE3 inhibition enhances contraction and peak-Ca 2+ transients and amplifies β-AR stimulation, whereas PDE1 inhibition does not. PDE1 inhibition augments Fsk-stimulated cAMP and cell shortening without increasing Ca 2+ , whereas PDE3 inhibition increases both shortening and Ca 2+ yet does not increase whole-cell measurable cAMP. Collectively, these in vivo and in vitro results define a pharmacological profile of ITI-214 that is different from β-AR agonism and PDE3 inhibition, and suggests potential utility as a clinical HF therapeutic engaging novel mechanisms. Indeed, we confirm that increases of PDE1 isoform expression occur in human patients with HF.
Given the array of cyclic nucleotide-signaling effects, the multiple cyclases involved in their synthesis, and >100 PDE isoforms engaged in their hydrolysis, it is not surprising that this regulation is highly compartmentalized within the cell. 10 In the case of cAMPregulating proteins, this transpires in conjunction with the A-kinase-anchoring proteins that coalesce these regulating proteins within nanodomains. 33 PDE3, the focus of much prior cardiac research and the only species currently used for clinical HF, exists in different isoforms: PDE3A1 localizes to the sarcoplasmic reticular- 34 and its inhibition induces positive inotropic effects in conjunction with increasing whole-Ca 2+ transients. 32 Different PDE isoforms also couple with β-AR signaling, with PDE4 playing a prominent role in modulating inotropic responses in rodents, 35 whereas, in larger mammals such as the dog, PDE3 plays a greater role. 36 The localization of PDE1 isoforms is less well studied, with 1 study showing PDE1C primarily in the soluble fraction of human myocytes, displaying a striated distribution that may reflect T-tubule mitochondria junctions. 22 In the current study, evidence for microdomain regulation by PDE1 was provided by the whole-cell cAMP measurements that showed little change despite Iso, Cil, or Iso+Cil stimulation, whereas each of these stimuli at identical concentrations augmented myocyte shortening and calcium transients. Fsk stimulates cAMP synthesis in multiple compartments as it targets adenyl cyclase directly, and here we did detect a rise in cAMP that further increased with ITI-214; Iso+ITI-214 did not alter cAMP. This is consistent with a prior study using Förster resonance energy transfer biosensors in adult mouse myocytes, where a rise in cAMP with PDE1 inhibition was impacted by Fsk and not β-AR costimulation. 37 That cAMP appeared similar with Fsk and Fsk+Cil further supports different compartments being engaged.
Although we did not directly probe for the subcellular cAMP-signaling compartments controlled by PDE1, we obtained substantial evidence supporting differences to cAMP regulation by β-AR activation or PDE3 inhibition. PDE1 inhibition failed to potentiate β-AR stimulation (in vivo and in vitro), unlike what occurs with PDE3 inhibition. In addition, ITI-214 did not augment whole-Ca 2+ transients, whereas this is observed with Iso stimulation±PDE3 inhibition. 38 The lack of Ca 2+ increase was still seen even when ITI-214 did enhance cell function, as when combined with Fsk. By contrast, PDE3 inhibition increased both function and Ca
2+
. This is notable because prior safety concerns regarding PDE3 inhibitors often noted their effects on increasing myocyte Ca 2+ , including arrhythmia. 13 The lack of intracellular Ca 2+ increase despite functional improvement suggests that PDE1 inhibition likely enhances phosphorylation of sarcomere proteins to improve myofilament calcium sensitivity. Furthermore, the ability of ITI-214 to accelerate the rate of Ca 2+ decline even as peak levels were slightly reduced suggests it also modulates internal Ca 2+ recycling and, less so, intracellular Ca 2+ entry. The precise targets remain to be determined.
Another major new finding was the capacity of an A 2B R antagonist to block ITI-214 cardiovascular effects in vivo. The heart expresses multiple adenosine receptors, including A 1, A 2A , A 2B , and A 3 . A 1 R and A 3 R couple to inhibitory G-proteins (G i,0 ) and G q/11 signaling, and blunt β-AR stimulation. 39 By contrast, A 2A and A 2B couple with stimulatory G s -cAMP, although regulation of contraction by the former may relate to blunting A 1 R-antiadrenergic effects, whereas A 2B R reportedly has more direct effects. 31 Work from the Kitakaze, 40 Strasser, 41 and Downey 42 laboratories showed A 2B R as an important mediator of ischemic protection, 43, 44 with benefits in human HF. Immunohistochemistry localizes A 2B R at mitochondria, 45 and it is also expressed in vascular tissue and fibroblasts, where it regulates proliferation, vascular tone, and antifibrotic signaling. 46 PDE1 inhibition is also antifibrotic, 47 regulates smooth muscle proliferation, 48 and, as shown by Zhang et al, 49 protects against doxorubicin-induced myocyte apoptosis in vitro and in vivo. In this study, they found that PDE1 colocalizes with A 2 R in a membrane macromolecular complex overlapping T tubules, and that both A 2A R and A 2B R blockade prevents the antiapoptotic efficacy from PDE1 inhibition. Although we found A 2B R blockade sufficient to prevent acute inotropic and vasodilator responses to ITI-214 in vivo, the A 2A R may also play a role, and this will require further investigation.
For the in vivo studies, we left reflexes intact so responses potentially relevant to humans could be observed. Although positive chronotropic and inotropic effects of ITI-214 could conceivably result from reflex activation, systolic pressure actually rose, which would be an overcompensation and unusual for a reflex mechanism. Its persistence with β-AR blockade and fixed rate pacing further counters the likelihood that ITI-214 inotropy was attributable to a baroreflex. Based on recent data, the HR changes are more likely related to PDE1 modulation of sinoatrial nodal cells, 26 although involvement of central or peripheral nervous signaling cannot be ruled out. We were surprised to find A 2B R blockade prevented HR rate increases, and cannot find studies linking this pathway to rate control, so other factors may apply. From a translational perspective, our data predict that, in patients with HF, most receiving β-AR blockade, ITI-214 should change HR little while still potentially conferring inotropic, lusitropic, and systemic vascular effects. The effect of ITI-214 on myocardial oxygen consumption remains to be determined, although, if A 2B R signaling dominates, we would predict little rise in contrast to β-AR stimulants.
ITI-214 is the only potent and selective PDE1 inhibitor yet developed and tested in humans, because it has successfully completed several phase I clinical trials. These studies have not focused on the cardiovascular system at all, but on important central nervous system functions that are impacted in neurodegenerative and neuropsychiatric disease. These earlier studies provided the safety data in support of a current phase Ib/IIA dosing, safety, and tolerance study of ITI-214 in stable patients with class II to III HF (NCT03387215). This study will assess the impact of ITI-214 on cardiovascular function in humans for the first time, and help determine if
